Stocks · News reference
Guggenheim analyst Michael Schmitz reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $45 price target.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Top analysts changed outlook on top names. For all changes, see analyst ratings page. AVBP $47, PGR $200, AEP $139, INTU $430, BCSF $13, GEMI $6, VEEV $275.
Read original at benzingaHC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $44 to $47.
Read original at benzingaCitigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $43 to $40.
Read original at benzinga